利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.02 秒)

    Inhibition of cell death responses induced by oxidative stress
    5.
    发明申请
    Inhibition of cell death responses induced by oxidative stress 审中-公开
    抑制氧化应激引起的细胞死亡反应

    公开(公告)号：US20060128720A1

    公开(公告)日：2006-06-15

    申请号：US10518665

    申请日：2003-03-20

    申请人： Donald Kufe ,  Rima Kaddurah-Daouk

    发明人： Donald Kufe ,  Rima Kaddurah-Daouk

    IPC分类号： A61K31/506

    CPC分类号： A61K31/513 ,  A61K31/505 ,  A61K31/506

    摘要： The invention provides methods of reducing or preventing oxidative stress-induced cell death by contacting a cell with a compound that inhibits the kinase activity and/or the mitochondrial translocation of c-Abl. The methods of the invention can be used to treat individuals individual diagnosed as having or being at risk of contracting a disorder characterized by excessive oxidative stress-induced cell death.

    摘要翻译： 本发明提供了通过使细胞与抑制c-Abl的激酶活性和/或线粒体易位的化合物接触来减少或预防氧化应激诱导的细胞死亡的方法。 本发明的方法可用于治疗个体被诊断为具有或处于以过度氧化应激诱导的细胞死亡为特征的疾病的风险中的个体。

    CONSTITUTIVE GENE EXPRESSION IN CONJUNCTION WITH IONIZING RADIATION
    6.
    发明申请
    CONSTITUTIVE GENE EXPRESSION IN CONJUNCTION WITH IONIZING RADIATION 有权
    与辐射相关的组成型基因表达

    公开(公告)号：US20080118471A1

    公开(公告)日：2008-05-22

    申请号：US12019428

    申请日：2008-01-24

    申请人： Ralph Weichselbaum ,  Dennis Hallahan ,  Donald Kufe ,  Vikas Sukhatme

    发明人： Ralph Weichselbaum ,  Dennis Hallahan ,  Donald Kufe ,  Vikas Sukhatme

    IPC分类号： A61K48/00

    CPC分类号： A61K48/005 ,  C12N2799/022

    摘要： The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are pharmacological preparations to be used to increase the levels of radiosensitizing compounds such as TNF-α, or radioprotective compounds such as MnSOD, in specified tissues or tumors of a subject.

    摘要翻译： 本公开内容显示了与辐射照射联合施用于细胞，组织或患者的与编码放射增敏剂或放射防护因子的基因有效连接的组成型启动子的成功应用。 还公开了用于在受试者的特定组织或肿瘤中增加放射增敏化合物如TNF-α或放射防护化合物如MnSOD的药理学制剂。

    USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA
    7.
    发明申请
    USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA 审中-公开
    包含TEMOZOLOMIDE和TNF-ALPHA联合治疗GLIOBLASTOMA的应用

    公开(公告)号：US20070212298A1

    公开(公告)日：2007-09-13

    申请号：US11574108

    申请日：2005-08-25

    申请人： Ralph Weichselbaum ,  Donald Kufe

    发明人： Ralph Weichselbaum ,  Donald Kufe

    IPC分类号： A61K38/19 ,  A61K51/00 ,  C07K14/52 ,  C12N5/08

    CPC分类号： A01K67/0271 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K31/41 ,  A61K38/191 ,  A61K41/0038 ,  A61K2300/00

    摘要： Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Pharmaceutical combinations and therapeutic combinations suitable for use in the methods of the invention are also disclosed.

    摘要翻译： 公开了协同抑制神经胶质瘤细胞生长的方法，包括使细胞与替莫唑胺和TNFα或与替莫唑胺，TNFα和辐射接触。 还公开了协同抑制人类癌症患者中神经胶质瘤生长的方法，包括给予替莫唑胺和TNFα，或与替莫唑胺，TNFα和辐射。 还公开了适用于本发明方法的药物组合和治疗组合。

    MUC1 and ABL
    9.
    发明申请
    MUC1 and ABL 审中-公开
    MUC1和ABL

    公开(公告)号：US20080107661A1

    公开(公告)日：2008-05-08

    申请号：US11829687

    申请日：2007-07-27

    申请人： Donald Kufe

    发明人： Donald Kufe

    IPC分类号： A61K38/00 ,  C12Q1/48 ,  G06G7/48 ,  A61K31/195 ,  A61P43/00 ,  C12N5/06 ,  A61K39/395

    CPC分类号： G01N33/5011 ,  G01N2333/4725 ,  G01N2333/91215 ,  G01N2500/02

    摘要： The present disclosure provides methods of identifying and making compounds and pharmaceutical compositions thereof that inhibit the interaction between MUC1 and Abl. The invention also provides in vivo, in vitro, and ex vivo methods of inhibiting such an interaction. Also featured are in vitro and in vivo methods of stimulating the Abl-dependent apoptotic pathway in cells expressing MUC1. In such methods, the compounds, compositions, and methods described herein are generally useful in the treatment of various cancers. The disclosure also provides methods for inhibiting Abl, and such methods, and compounds and compositions for use in the methods are generally useful for the treatment of cancers, inflammatory conditions, atherosclerotic lesions, and neurologic disorders.

    摘要翻译： 本公开提供了鉴定和制备抑制MUC1和Ab1之间的相互作用的化合物及其药物组合物的方法。 本发明还提供了抑制这种相互作用的体内，体外和离体方法。 还特征在于在表达MUC1的细胞中刺激Abl依赖性凋亡途径的体外和体内方法。 在这些方法中，本文所述的化合物，组合物和方法通常可用于治疗各种癌症。 本公开还提供了抑制Abl的方法，并且用于该方法的这些方法和化合物和组合物通常可用于治疗癌症，炎性病症，动脉粥样硬化病变和神经障碍。